Tacedinaline

Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC50s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.

Product Specifications

CAS Number

[112522-64-2]

Product Name Alternative

N-acetyldinaline; CI-994; Goe-5549

UNSPSC

12352005

Hazard Statement

H319

Target

Apoptosis; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CI-994.html

Purity

99.32

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(NC1=C(N)C=CC=C1)C2=CC=C(NC(C)=O)C=C2

Molecular Formula

C15H15N3O2

Molecular Weight

269.30

Precautions

H319

References & Citations

[1]Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50 (23) :5543-6.|[2]Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15 (1) :39-48.|[3]LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14 (4) :349-56.|[4]Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73 (3) :168-74.